Literature DB >> 11236807

A brief introduction to Monte Carlo simulation.

P L Bonate1.   

Abstract

Simulation affects our life every day through our interactions with the automobile, airline and entertainment industries, just to name a few. The use of simulation in drug development is relatively new, but its use is increasing in relation to the speed at which modern computers run. One well known example of simulation in drug development is molecular modelling. Another use of simulation that is being seen recently in drug development is Monte Carlo simulation of clinical trials. Monte Carlo simulation differs from traditional simulation in that the model parameters are treated as stochastic or random variables, rather than as fixed values. The purpose of this paper is to provide a brief introduction to Monte Carlo simulation methods.

Mesh:

Year:  2001        PMID: 11236807     DOI: 10.2165/00003088-200140010-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  5 in total

Review 1.  Simulation of clinical trials.

Authors:  N H Holford; H C Kimko; J P Monteleone; C C Peck
Journal:  Annu Rev Pharmacol Toxicol       Date:  2000       Impact factor: 13.820

Review 2.  Clinical trial simulation in drug development.

Authors:  P L Bonate
Journal:  Pharm Res       Date:  2000-03       Impact factor: 4.200

3.  A mixture model for longitudinal data with application to assessment of noncompliance.

Authors:  D K Pauler; N M Laird
Journal:  Biometrics       Date:  2000-06       Impact factor: 2.571

4.  Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine.

Authors:  N H Holford; K E Peace
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

5.  A Markov mixed effect regression model for drug compliance.

Authors:  P Girard; T F Blaschke; H Kastrissios; L B Sheiner
Journal:  Stat Med       Date:  1998-10-30       Impact factor: 2.373

  5 in total
  22 in total

1.  Pharmacokinetic-pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries.

Authors:  A Canut; A Isla; C Betriu; A R Gascón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-02-28       Impact factor: 3.267

2.  Population Pharmacokinetics and Dosing Optimization of Imipenem in Children with Hematological Malignancies.

Authors:  Lei Dong; Xiao-Ying Zhai; Yi-Lei Yang; Li Wang; Yue Zhou; Hai-Yan Shi; Bo-Hao Tang; Yue-E Wu; Fan Yang; Li Wen; Hong-Xiao Kong; Li-Juan Zhi; Evelyne Jacqz-Aigrain; Wei Zhao
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

3.  Covariate detection in population pharmacokinetics using partially linear mixed effects models.

Authors:  Peter L Bonate
Journal:  Pharm Res       Date:  2005-04-07       Impact factor: 4.200

4.  Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation.

Authors:  Steve N Caritis; Shringi Sharma; Raman Venkataramanan; Dwight J Rouse; Alan M Peaceman; Anthony Sciscione; Catherine Y Spong; Michael W Varner; Fergal D Malone; Jay D Iams; Brian M Mercer; John M Thorp; Yoram Sorokin; Marshall Carpenter; Julie Lo; Susan Ramin; Margaret Harper
Journal:  Am J Obstet Gynecol       Date:  2011-03-22       Impact factor: 8.661

5.  Pharmacokinetics of aztreonam in healthy subjects and patients with cystic fibrosis and evaluation of dose-exposure relationships using monte carlo simulation.

Authors:  Alexander A Vinks; Ronald N van Rossem; Ron A A Mathôt; Harry G M Heijerman; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2007-06-18       Impact factor: 5.191

6.  The effect of poor compliance on the pharmacokinetics of carbamazepine and its epoxide metabolite using Monte Carlo simulation.

Authors:  Jun-jie Ding; Yun-jian Zhang; Zheng Jiao; Yi Wang
Journal:  Acta Pharmacol Sin       Date:  2012-10-29       Impact factor: 6.150

7.  Variability in Human In Vitro Enzyme Kinetics.

Authors:  Christopher R Gibson; Ying-Hong Wang; Ninad Varkhede; Bennett Ma
Journal:  Methods Mol Biol       Date:  2021

8.  Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia.

Authors:  Juan L Rodríguez-Tudela; Benito Almirante; Dolors Rodríguez-Pardo; Fernando Laguna; J Peter Donnelly; Johan W Mouton; Albert Pahissa; Manuel Cuenca-Estrella
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

9.  Population pharmacokinetics of tacrolimus in children with nephrotic syndrome.

Authors:  Guo-Xiang Hao; Xin Huang; Dong-Feng Zhang; Yi Zheng; Hai-Yan Shi; Yan Li; Evelyne Jacqz-Aigrain; Wei Zhao
Journal:  Br J Clin Pharmacol       Date:  2018-05-22       Impact factor: 4.335

10.  Pharmacokinetics of mycophenolate mofetil in children with lupus and clinical findings in favour of therapeutic drug monitoring.

Authors:  Jean-Baptiste Woillard; Brigitte Bader-Meunier; Rémi Salomon; Bruno Ranchin; Stéphane Decramer; Michel Fischbach; Etienne Berard; Vincent Guigonis; Jérôme Harambat; Olivier Dunand; Julie Tenenbaum; Pierre Marquet; Franck Saint-Marcoux
Journal:  Br J Clin Pharmacol       Date:  2014-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.